-
Sinovac Partners with Brazil’s Fiocruz to Boost Vaccine Research and Development
•
Fiocruz, a renowned health research center based in Brazil, has announced a collaboration agreement with China’s Sinovac Biotech Ltd. (NASDAQ: SVA) to jointly engage in the research and development of vaccines. The financial details of the partnership have not been disclosed. This collaboration comes on the heels of a meeting…
-
Sinovac Biotech Commits USD 100 Million Investment in Brazil for Vaccine Research and Collaboration
•
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading vaccine specialist based in China, is reportedly set to invest USD 100 million in the Brazilian market to bolster collaborations with local partners and researchers. The company plans to conduct in-country research not only on vaccines but also on advanced therapeutics, including cell…
-
Sinovac Biotech Ltd Dismisses UK Private Equity’s Nominal Share Acquisition Offer
•
Sinovac Biotech Ltd (NASDAQ: SVA) has released a statement declaring that its board of directors has unanimously resolved to dismiss a nominal offer by UK-based private equity firm Alternative Liquidity Index LP to acquire up to 10 million of the company’s shares for USD 0.03 each. The board asserts that…
-
Sinovac Biotech Advances SA55 COVID-19 Neutralizing Antibody into Phase II Trials
•
China-based vaccines firm Sinovac Biotech Ltd (NASDAQ: SVA) has announced the completion of a Phase I trial and the immediate initiation of a Phase II study for its broad-spectrum COVID-19 neutralizing antibody, SA55. The molecule, which was first approved to enter clinical trials in China on May 24 this year,…
